Brief: Akari Therapeutics - Files To Offer Up To 2.5 Million Adss Via White Lion Capital - SEC Filing
27/06/2026 24:01
BRIEF-Akari Therapeutics - Files To Offer Up To 2.5 Million Adss Via White Lion Capital - SEC Filing June 26 (Reuters) - Akari Therapeutics PLC AKTX.O:
AKARI THERAPEUTICS - FILES TO OFFER UP TO 2.5 MILLION ADSS VIA WHITE LION CAPITAL - SEC FILING
Source text: [ID:n0001493152-26-030330]
Further company coverage: AKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics